3 recruiting, 1 completed, 1 terminated. 5 Phase 1, 3 Phase 2.
By phase and status
Follow CAPOX: new trials by email Literature Review of CAPOX trials Research Report on CAPOX
Trials (filtered) newest first · largest first
All 5 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
ATG-022, pembrolizumab/KEYTRUDA®, CAPOX - Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | 132 | 2026-02-27 | 2026-07-29 |
Preoperative Radiotherapy And ASTX660 in Rectum Cancer
mFOLFIRINOX, Pelvic radiotherapy LCRT, Capecitabine - Locally-advanced Rectal Cancer | Phase 1 | Recruiting | 78 | 2023-12-19 | 2024-02-08 |
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
Spevatamig (PT886), Paclitaxel, Gemcitabine - Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | 350 | 2023-03-15 | 2026-09-28 |
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin
Irinotecan, CAPOX - Gastric Cancer, Peritoneal Metastases | Phase 1 | Completed | 20 | 2022-05-25 | 2025-04-01 |
A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
Bemarituzumab, CAPOX, SOX - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Terminated | 72 | 2022-05-17 | 2026-07-29 |
Conditions studied
Stomach Neoplasms (2) · Biliary Tract Neoplasms (1) · Colorectal Neoplasms (1)
Sponsors
Amgen (1) · Antengene Biologics Limited (1) · Erasmus Medical Center (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Phanes Therapeutics (1)
Countries
United States (2) · China (1) · France (1) · Japan (1) · Netherlands (1) · Singapore (1) · South Korea (1) · Taiwan (1)
Top investigators
Ron Mathijssen, Professor (1)